Mumbai, June 16 -- This move is part of a "structured and forward-looking succession planning process," the company stated, aimed at ensuring leadership continuity. The appointment is subject to shareholder approval at the upcoming Annual General Meeting.
Dilip Shanghvi, the current managing director, will step down from the role and transition to executive chairman of the board. In his new capacity, Shanghvi will dedicate his efforts to bolstering Sun Pharma's high-growth specialty portfolio and providing strategic oversight for the company's long-term vision.
Ganorkar, a Sun Pharma veteran who joined the company in 1996, has been instrumental in the company's growth. He has successfully spearheaded the India business since June 2019, si...